Urine Drug Testing Billing Audits for SUD Clinics: Medical Necessity, Frequency, and Lab Compliance

Urine drug testing is one of the most audited services in SUD treatment. Learn how presumptive and definitive testing are billed, what OIG found, and how SUD clinics can document medical necessity and frequency.

KNOWLEDGE CENTER

11/15/202612 min read

Urine drug testing is a valuable clinical tool in substance use disorder (SUD) treatment. Testing helps clinicians confirm self-reported use, detect substances that may complicate treatment, monitor adherence to medications for opioid use disorder, and adjust the level of care. Used thoughtfully, it supports recovery.

Urine drug testing is also one of the most frequently audited and prosecuted services in behavioral health. Payment for definitive testing increases with the number of drug classes tested, testing can be ordered repeatedly for every patient, and laboratories, clinics, and recovery residences can be connected through financial relationships. The U.S. Department of Health and Human Services Office of Inspector General (OIG) has issued multiple reports on Medicare drug testing payments, including a 2023 report estimating that Medicare could have saved up to $216 million over five years if program safeguards had prevented at-risk payments for the highest-paying definitive drug testing code. State Medicaid agencies and managed care plans have set testing limits, prior authorization requirements, and edits. And drug testing schemes appear regularly in federal health care fraud enforcement.

This article explains how drug testing is billed, what auditors look for, and how SUD clinics can build ordering, documentation, and laboratory practices that withstand review. It focuses on clinics that order tests and on clinics that perform testing in their own laboratories. It is educational and neutral. Coverage rules vary by payer and state, so clinics should confirm requirements with their Medicare Administrative Contractor (MAC), state Medicaid agency, and managed care plans.

Presumptive Versus Definitive Testing

Drug testing falls into two broad categories.

Presumptive Testing

Presumptive tests, often called screening tests, use methods such as immunoassay cups, dipsticks, or analyzers to indicate whether a drug or drug class is likely present or absent. Results are qualitative and can produce false positives or negatives. In the CPT code set, presumptive testing is reported with codes 80305, 80306, and 80307, which are distinguished by the testing method, not the number of drugs tested. Presumptive testing is generally inexpensive.

Definitive Testing

Definitive tests use methods such as liquid or gas chromatography with mass spectrometry to identify specific drugs and metabolites and, often, their quantities. For Medicare, definitive testing is reported with HCPCS codes G0480 through G0483, which are tiered by the number of drug classes tested: 1 to 7, 8 to 14, 15 to 21, and 22 or more. Payment rises with each tier. Many Medicaid programs and commercial payers use the same codes or related CPT codes.

Why the Distinction Matters

Clinically, definitive testing is typically used to confirm an unexpected presumptive result, to identify a specific substance when presumptive testing is not available or reliable for it, or to answer a specific clinical question. Auditors look for definitive testing ordered routinely for all patients, at the highest tier, without a documented reason.

What OIG Found

2021: Weaknesses in Program Safeguards

In June 2021, OIG reported that for 2019, Medicare paid $180 million for drug testing services provided to 274,000 beneficiaries with SUD nationwide. OIG assessed the Medicare contractors' program safeguards and identified several weaknesses in those safeguards for preventing and detecting improper payments for drug testing and promoting provider compliance. OIG also noted that contractors did not have clear or consistent requirements for determining the number of drug classes to bill for definitive drug testing.

2023: Up to $216 Million in At-Risk Payments

In February 2023, OIG reported on Medicare Part B payments for definitive drug testing from 2016 through 2020. OIG focused on procedure code G0483, definitive drug testing for 22 or more drug classes, which is the definitive code with the highest reimbursement. OIG identified "at-risk providers" that routinely billed G0483 for a large share of their definitive testing and estimated that Medicare could have saved up to $216 million over five years if program safeguards had prevented at-risk payments. OIG recommended that CMS expand program safeguards and review payments to at-risk providers to recover overpayments.

Continuing Work

OIG's work plan has included audits of Medicare payments for definitive drug testing by individual laboratory providers, and OIG has stated it will use the results to identify laboratories or other institutions that routinely submit improper claims, including providers that regularly bill at the highest reimbursement amount.

Medical Necessity: The Core Requirement

Medicare covers drug testing when it is reasonable and necessary for the diagnosis or treatment of the individual patient. Medicaid programs apply similar standards through their own policies. MACs have issued local coverage determinations and articles for controlled substance monitoring and drugs of abuse testing that describe when testing is covered for patients in SUD treatment, what the treating practitioner must document, and limits on frequency and panel size. Clinics should read the policy that applies to their jurisdiction and payer.

Common principles across payers include:

• Testing must be ordered by the treating practitioner for the individual patient.

• The order must specify the tests or drug classes to be performed, rather than relying on a standing order that tests every patient for everything.

• The medical record must explain why each test is needed, how the results will be used, and why definitive testing is necessary when presumptive testing would suffice.

• The frequency of testing should reflect the patient's phase of treatment, clinical stability, and risk, and should change as the patient's situation changes.

• Results must be reviewed and used in treatment decisions.

• Testing for non-medical purposes, such as employment, court orders, residential house rules, or sports, is generally not covered.

Standing Orders and Blanket Panels

Standing orders, which automatically trigger the same tests at the same frequency for all patients, are among the most cited problems in drug testing audits. Payers generally require individualized orders. A clinic may use protocols that guide clinicians, but the order for each patient should reflect that patient's history and current risk.

Similarly, blanket panels that test every specimen for 22 or more drug classes, regardless of the patient's history or local drug supply, draw attention. Auditors look for evidence that the clinician selected drug classes based on the patient's substances of use, prescribed medications, and community trends.

Frequency

Payers limit or scrutinize testing frequency. Early in treatment, more frequent testing may be clinically appropriate. As patients stabilize, frequency usually decreases. Testing at the same high frequency for every patient throughout treatment, or testing far more often than the treatment plan calls for, is a red flag.

Clinics should document the planned testing frequency in the treatment plan, explain the reason, and update it when the patient's stability changes. Some state Medicaid programs set numeric annual limits on presumptive and definitive testing, with prior authorization or medical necessity review above the limit. Clinics must know these limits and track each patient's tests against them.

Results Review and Clinical Use

Auditors check whether results were reviewed and used. A note showing that the clinician reviewed the result, discussed it with the patient, and adjusted treatment where appropriate supports medical necessity. Results that arrive after the patient's next visit, are never reviewed, or have no effect on care undermine the case for testing.

Turnaround time matters. If definitive results routinely arrive weeks later, auditors may question whether they could have informed treatment.

In-Office Testing and CLIA

Clinics that perform presumptive testing on site must hold the appropriate certificate under the Clinical Laboratory Improvement Amendments (CLIA). Many point-of-care cups are CLIA-waived tests, which require a Certificate of Waiver; more complex analyzers require a higher certificate. Clinics that perform definitive testing in-house operate high-complexity laboratories with significant regulatory requirements. The CLIA certificate type must match the tests performed, and billing must use the correct modifiers where required.

Clinics should keep CLIA certificates current, follow manufacturer instructions, maintain quality control records, and make sure staff performing tests are trained and competent.

Laboratory Relationships and Kickback Risk

Relationships between SUD clinics, recovery residences, and laboratories are a major enforcement focus. Risky arrangements include:

• A laboratory paying a clinic, recovery residence, or marketer for each specimen referred.

• A laboratory providing free staff, specimen collectors, supplies beyond those needed for its own tests, or electronic health record systems to a referring clinic.

• Sham consulting, medical director, or marketing agreements that disguise per-referral payments.

• Clinics or recovery residences that receive a share of laboratory revenue.

• Clinics that bill for tests actually performed by an outside laboratory.

These arrangements can violate the federal Anti-Kickback Statute, 42 U.S.C. 1320a-7b(b), the physician self-referral law where applicable, and the Eliminating Kickbacks in Recovery Act, 18 U.S.C. 220, which specifically covers remuneration for referrals to laboratories, recovery homes, and clinical treatment facilities. State patient brokering and anti-kickback laws may also apply. Any arrangement with a laboratory should be in writing, at fair market value, unrelated to the volume or value of referrals, and reviewed by counsel.

Recovery Housing and Drug Testing

Drug testing in recovery residences deserves special attention. Recovery housing operators often test residents to enforce house rules. That is a housing function. When residents' specimens are sent to a laboratory and billed to Medicaid or commercial insurance as medically necessary testing ordered by a clinic, without an individualized clinical order and use, the claims are at risk. Patterns of high-volume definitive testing of residents of the same addresses are well known to investigators.

Medicaid and Managed Care Policies

State Medicaid programs and managed care plans set their own drug testing rules. Common features include:

• Annual limits on presumptive and definitive tests per patient.

• Prior authorization for definitive testing above a threshold or at higher tiers.

• Requirements that definitive testing follow a presumptive result except in defined circumstances.

• Restrictions on which provider types may order testing.

• Bundling of testing into certain program rates, such as opioid treatment program bundles.

The last point is important. Where testing is included in a bundled rate, as it is in Medicare's opioid treatment program bundle, which covers toxicology testing if performed, separately billing the same testing can create duplicate payment. Clinics should confirm whether testing is bundled in each program they bill.

Documentation Checklist

For each test billed, the record should contain:

• An individualized order from the treating practitioner specifying the test type and drug classes.

• The clinical reason for the test, including why definitive testing is needed when it is ordered.

• The patient's substances of use and prescribed medications relevant to test selection.

• The planned frequency documented in the treatment plan, with reasons for any change.

• Specimen collection information, including date and chain-of-custody documentation where applicable.

• The result, the date received, and evidence the clinician reviewed it.

• Evidence the result was discussed with the patient and used in care decisions.

• For in-house testing, the CLIA certificate and quality control records.

Common Audit Findings

• No order, or a standing order without individualized selection.

• Definitive testing at the highest tier for most or all specimens.

• Definitive testing without documented reason after a negative or expected presumptive result.

• Testing far more frequently than the treatment plan or payer policy allows.

• Results not reviewed or not used.

• Testing billed for non-covered purposes such as house rules or court requirements.

• Testing billed separately when included in a bundle.

• Tests billed by the clinic but performed by another laboratory.

• CLIA certificate missing or not matching the test complexity.

• Financial relationships with laboratories or recovery residences that raise kickback concerns.

Building a Compliant Drug Testing Program

Write a Clinical Drug Testing Policy

Set out when presumptive and definitive testing are used, how drug classes are selected, how frequency is determined and adjusted by phase of treatment, how results are reviewed and acted upon, and which purposes are not billable.

Train Prescribers

Teach clinicians to write individualized orders, document reasons, select drug classes thoughtfully, and record how results changed care.

Configure Systems

Configure the electronic health record and laboratory order interface so standing panels cannot be applied automatically to all patients, and so the clinician must select drug classes and enter a reason for definitive testing.

Track Limits

Monitor each patient's testing against payer limits and authorizations.

Audit Regularly

Each month, review a sample of tests for order, reason, frequency, results review, and correct coding. Track the distribution of definitive testing tiers. If most definitive tests are billed at G0483 or its equivalent, investigate why.

Review Laboratory and Housing Relationships

Have counsel review all relationships with laboratories, marketers, and recovery residences.

Correct and Refund

Report and return identified overpayments within the timeframe required under section 1128J(d) of the Social Security Act and applicable state law.

Responding to a Drug Testing Audit

• Identify the auditor and payer rules that apply, including the MAC's coverage policy or the state Medicaid policy in effect on each date of service.

• Gather orders, treatment plans, results, and notes showing review and use for each sampled test.

• Retrieve laboratory requisitions and reports to confirm what was ordered and performed.

• Prepare a clinical explanation for frequency and panel selection where the record supports it.

• Review whether any tests were bundled, duplicated, or performed for non-covered purposes.

• Respond to findings claim by claim, and scrutinize any statistical extrapolation.

• Develop a corrective action plan addressing root causes such as standing orders or default panels.

• Involve counsel if the audit involves laboratory relationships or suggests fraud.

Drug Testing in Medication Programs

Clinics that prescribe buprenorphine or other medications for opioid use disorder often test to confirm the presence of the prescribed medication and to detect other substances. That purpose is clinically legitimate, but it still requires an individualized order, a documented reason, and appropriate frequency. A positive result for a non-prescribed substance should prompt a documented clinical response, such as a discussion with the patient, a change in visit frequency, or a referral to a higher level of care. Clinicians should also document how test results inform decisions about prescription length and the number of days supplied, because those decisions are often reviewed alongside testing.

Clinics should avoid using drug test results punitively in ways that are not clinically grounded, such as automatic discharge after a single positive result, because such policies can raise quality and access concerns and do not support the medical necessity of testing.

Telehealth and Remote Specimen Collection

As more SUD care is delivered by telehealth, some clinics use remote or home specimen collection. Payers may have specific rules about who may collect specimens, how chain of custody is maintained, and whether remote collection is covered. Clinics using these methods should confirm payer policies, document collection procedures, and make sure the ordering practitioner still individualizes the order and reviews the result. Where a laboratory provides collection services, the arrangement should be reviewed for kickback risk, because free collection staff or services provided to a referring clinic can be considered remuneration.

Coordinating With Reference Laboratories

Clinics that send specimens to outside laboratories should make sure requisition forms allow clinicians to select individual drug classes rather than forcing a large default panel. Clinics should ask laboratories to provide reports in time to inform the next visit and should reconcile laboratory bills against orders periodically. If a laboratory bills for more classes than the clinician ordered, the clinic should raise the issue with the laboratory and document it.

Myths About Drug Testing Billing

Myth: More Testing Shows Better Care

Payers expect testing to be individualized. Testing everyone frequently at the highest tier suggests a business model, not clinical judgment.

Myth: A Signed Standing Order Is Enough

Most payers require individualized orders that reflect the patient's history and needs.

Myth: The Laboratory Is Responsible for Medical Necessity

Laboratories bill the tests, but the ordering practitioner's documentation establishes medical necessity. Both can face consequences.

Myth: Testing for House Rules Can Be Billed if a Clinic Signs Off

Testing for non-medical purposes is generally not covered, even if a clinician signs the order.

Questions Leadership Should Ask

• Are all drug test orders individualized, with drug classes selected for the patient?

• What share of our definitive tests are billed at the highest tier, and why?

• Does testing frequency change as patients stabilize?

• Are results reviewed promptly and used in care?

• Is testing bundled into any rates we bill?

• Do our CLIA certificates match the tests we perform?

• Do we have any financial relationships with laboratories, marketers, or recovery residences?

Key Takeaways

• Presumptive testing (80305 to 80307) and definitive testing (G0480 to G0483 for Medicare) are paid differently, with definitive payment rising by drug class count.

• OIG found weaknesses in Medicare safeguards for drug testing and estimated up to $216 million in at-risk payments for the highest-tier definitive code over five years.

• Medical necessity requires individualized orders, documented reasons, appropriate frequency, and evidence that results were used.

• Standing orders, blanket high-tier panels, testing for house rules, and unbundling are common audit findings.

• Laboratory and recovery housing relationships carry significant kickback risk under the Anti-Kickback Statute, EKRA, and state law.

How HealthBridge Can Help

HealthBridge helps SUD clinics build drug testing programs that are clinically sound and audit-ready. Our team can review your drug testing policy, order sets, and electronic health record configuration; audit a sample of tests for individualized orders, documented reasons, frequency, results review, and correct coding; and analyze the distribution of your presumptive and definitive testing against payer expectations. We help clinics train prescribers, track payer limits, confirm CLIA compliance, identify bundling issues, and work with counsel to review laboratory and recovery housing relationships. If you receive a drug testing audit, we can help organize records, prepare responses, and develop a corrective action plan. If you want to strengthen your urine drug testing compliance, please get in touch with us. We will be happy to help you with this topic.

References

• HHS Office of Inspector General. Opportunities Exist for CMS and Its Medicare Contractors To Strengthen Program Safeguards To Prevent and Detect Improper Payments for Drug Testing Services (A-09-20-03017). https://oig.hhs.gov/reports/all/2021/opportunities-exist-for-cms-and-its-medicare-contractors-to-strengthen-program-safeguards-to-prevent-and-detect-improper-payments-for-drug-testing-services

• HHS Office of Inspector General. Medicare Could Have Saved up to $216 Million Over 5 Years if Program Safeguards Had Prevented At-Risk Payments for Definitive Drug Testing Services (A-09-21-03006). https://oig.hhs.gov/reports/all/2023/medicare-could-have-saved-up-to-216-million-over-5-years-if-program-safeguards-had-prevented-at-risk-payments-for-definitive-drug-testing-services

• HHS Office of Inspector General. Report in Brief, A-09-21-03006. https://www.oig.hhs.gov/documents/audit/9627/A-09-21-03006-Report%20in%20Brief.pdf

• HHS Office of Inspector General. Work Plan: Audits of Selected Independent Clinical Laboratory Billing Requirements (W-00-24-35726). https://oig.hhs.gov/reports/work-plan/browse-work-plan-projects/w-00-24-35726/

• Oversight.gov. Report A-09-21-03006. https://www.oversight.gov/reports/audit/medicare-could-have-saved-216-million-over-5-years-if-program-safeguards-had

• Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual, Chapter 39, Opioid Treatment Programs (Transmittal R13572CP). https://www.cms.gov/files/document/r13572cp.pdf

• Centers for Medicare & Medicaid Services. Clinical Laboratory Improvement Amendments (CLIA). https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments

• Electronic Code of Federal Regulations. 42 CFR Part 493, Laboratory Requirements. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493

• Electronic Code of Federal Regulations. 42 CFR 410.32, Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-410/subpart-B/section-410.32

• U.S. Code. 18 U.S.C. 220, Illegal remunerations for referrals to recovery homes, clinical treatment facilities, and laboratories. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title18-section220

• U.S. Code. 42 U.S.C. 1320a-7b, Criminal penalties for acts involving Federal health care programs. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1320a-7b

• U.S. Code. 42 U.S.C. 1320a-7k(d), Reporting and returning of overpayments. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1320a-7k


Some or all of the services described herein may not be permissible for HealthBridge US clients and their affiliates or related entities.

The information provided is general in nature and is not intended to address the specific circumstances of any individual or entity. While we strive to offer accurate and timely information, we cannot guarantee that such information remains accurate after it is received or that it will continue to be accurate over time. Anyone seeking to act on such information should first seek professional advice tailored to their specific situation. HealthBridge US does not offer legal services.

HealthBridge US is not affiliated with any department of public health agencies in any state, nor with the Centers for Medicare & Medicaid Services (CMS). We offer healthcare consulting services exclusively and are an independent consulting firm not affiliated with any regulatory organizations, including but not limited to the Accrediting Organizations, the Centers for Medicare & Medicaid Services (CMS), and state departments. HealthBridge is an anti-fraud company in full compliance with all applicable federal and state regulations for CMS, as well as other relevant business and healthcare laws. The badges, icons, and achievement graphics displayed on this website represent proprietary performance metrics, volume milestones, and internal corporate recognition issued exclusively by our corporate affiliate network at SummitRidge. These visual markers are utilized solely as historical indicators of enterprise growth, operational longevity, and volume-based milestones cleared within our shared corporate ecosystem.

© 2026 HealthBridge US, a California corporation. All rights reserved.

For more information about the structure of HealthBridge, visit www.myhbconsulting.com/governance

Legal

Resources